Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$11.85 USD
-0.89 (-6.99%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $11.86 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
OLMA 11.85 -0.89(-6.99%)
Will OLMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OLMA
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
Other News for OLMA
Commit To Buy Olema Pharmaceuticals At $10, Earn 48.8% Annualized Using Options
Olema Oncology price target lowered by $2 at JPMorgan, here's why
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
Buy Rating for Olema Pharmaceuticals Based on Promising Clinical Data and Strategic Drug Positioning